About Tempus AI Inc
- Industry: Life Sciences Tools & Services
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://investors.tempus.com/
Frequently Asked Questions
What is the 52-week range for TEM?
The 52-week high is $104.32 and the 52-week low is $40.77.
What is the P/E ratio for TEM?
The P/E ratio data is currently unavailable.
What is the dividend yield for TEM?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -54.70%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -17.77%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 21.38.
Analyst Recommendation Trends
Wall Street analyst consensus for TEM over the last few months:
Latest TEM News
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment
Towards Healthcare projects that the global AI in drug discovery market will grow from $19.89 billion in 2025 to $160.49 billion by 2035, a compound annual growth rate of 23.22%. Active Companies from around the markets with current developments this week include: MindWalk Holdings Corp. (NASDAQ: HYFT), AbCellera Biologics Inc. (NASDAQ: ABCL), Eli Lilly and Company (NYSE: LLY), Twist Bioscience Corporation (NASDAQ: TWST) and Tempus AI, Inc. (NASDAQ: TEM).
Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026
CHICAGO, October 01, 2026--Tempus AI, Inc. (NASDAQ: TEM) today announced that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid.
Stock Market Today: S&P 500 Slips as Micron Fails to Impress, 10-Year Yields Ease to 5.25%
Micron slides despite a record quarter as the 10-year yield nears 5.3% and oil tops $92, while Accenture, Coherent and Vicor surge on earnings and AI optics.
Guggenheim Maintains Buy on Tempus AI, Raises Price Target to $92
Guggenheim analyst Subbu Nambi maintains Tempus AI (NASDAQ:TEM) with a Buy and raises the price target from $65 to $92.
The Top HealthTech Questions Landing On Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation.
'HHS launches project to speed up clinical trials' - Axios
https://www.axios.com/2026/09/30/hhs-clinical-trials-redesign
Cathie Wood Sold $110 Million of AMD and Bought Nvidia Instead
Cathie Wood just dumped one of this year's biggest AI winners to load up on a stock that has barely moved, and the reasoning behind that swap reveals a lot about where she thinks the real opportunity still sits.
Personalis: The Wrong Side Of The Merger
Personalis shareholders remain exposed to downside in TEM shares while having limited ability to benefit from further TEM appreciation above $48.42. Learn more about PSNL stock here.
Providence Therapeutics Announces Formation of Oncology Clinical Advisory Board
Providence Therapeutics Holdings, Inc. is pleased to announce formation of its initial Clinical Advisory Board. This advisory group will help steer Providence's therapeutic mRNA cancer vaccine programs, including the Company's personalized vaccine program for pediatric brain cancer patients as well as the Company's off-the-shelf precision therapy vaccines for a range of solid tumor cancers.
Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress
Beam Therapeutics (BEAM) stock analysis: BEAM-302 gene-editing upside for 2028â2029, cash runway/dilution risks, valuation vs peersâread now.
Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation
CHICAGO, September 28, 2026--Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-MR, an AI product that analyzes standard 12-lead resting electrocardiograms (ECGs) to detect signs associated with undiagnosed moderate or severe mitral regurgitation (MR).
Tempus AI Receives 510(k) Clearance From FDA For Tempus ECG-MR, AI Product That Analyzes Standard 12-Lead Resting Ecgs To Detect Signs Associated With Undiagnosed Mitral Regurgitation
ECG-MR becomes the fourth FDA-cleared Tempus ECG-AI product, spanning arrhythmia, heart function, pulmonary vascular and valvular diseaseTempus AI, Inc. (NASDAQ:TEM) today announced it has received 510(k) clearance from
Tempus AI Chief Accounting Officer Sells $529,650 of Stock
Sale follows 30% rebound in the stock year to date.
Buy 3 AI-Powered Medical Stocks to Strengthen Your Portfolio in Q4
AI adoption is reshaping medical devices, with ISRG, TEM and TMO leveraging AI to advance precision medicine and drug development.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Tempus AI (TEM) Has a $75 Goldman Sachs Target, But Its Data Business Faces a Bigger Test
Goldman Sachs’ Neutral initiation of Tempus AI, Inc. (NASDAQ:TEM) on September 21 puts the company’s fastest-growing businesses under different tests: diagnostics offers visible near-term growth, while the data and applications segment faces renewal risk as several major contracts approach extensions over the next two years. The timing is notable because Tempus AI, Inc. (NASDAQ:TEM) announced […]
Tempus AI: High Risk, But With A Great Cause
Tempus AI remains a Buy as I increase my position, driven by strategic moves and accelerating growth. Click here to read an analysis of TEM stock now.
Tempus AI Sees Pricing, Data Growth Fueling Long-Term Expansion
Tempus AI (NASDAQ:TEM) Founder and CEO Eric Lefkofsky said the company’s second-quarter performance was supported by continued demand for comprehensive genomic profiling and growth in its data-licensing business. Speaking at Morgan Stanley’s Global Healthcare Conference, Lefkofsky said the diagnost
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model
CHICAGO, September 21, 2026--Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies have entered into a new agreement under which Tempus will license Recursion’s RNA Foundation Model.
Tempus AI Extends Recursion Data Deal Through 2029, Replacing Potential $84M Fees With $42M In Committed Payments, In Addition To Licensing Recursion’s RNA Foundation Model "TxFM" Under A Separate License Agreement
Tempus AI, Inc. (NASDAQ:TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX). Additionally, the two companies have entered into a new agreement under which
This Digital Realty Trust Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Wall Street initiated coverage on XRN, TEM, NNE, SECZ with ratings from Neutral to Buy and price targets of $21.20-$75.
Goldman Sachs Initiates Coverage On Tempus AI with Neutral Rating, Announces Price Target of $75
Goldman Sachs analyst Evie Koslosky initiates coverage on Tempus AI (NASDAQ:TEM) with a Neutral rating and announces Price Target of $75.
Tempus AI (TEM) Is Building a Heart Failure Agent That Never Sleeps
On September 9, Tempus AI (NASDAQ:TEM) said ARPA-H, a US health research agency, picked it to build an AI that treats heart failure patients without a clinician stepping in. The award is worth up to $9.5 million, which is small change for a company booking hundreds of millions in quarterly sales. But the dollars are […]
Tempus AI (TEM), What Is Behind The Latest Buzz?
Tempus AI (TEM) has put a new data project at the center of the story. The business plans a research platform built on 100,000 whole genomes linked to long term clinical records. Tempus AI’s new whole genome project arrives after a sharp run in the shares, with a 90 day share price return of 62.68% and a 7 day gain of 31.91%. However, the 1 year total shareholder return of an 11.79% decline shows the longer term picture has been more mixed despite the current momentum around the US$77.84...
Tempus AI (TEM) Is Up 31.9% After Launching 100,000‑Genome AI Research Platform Initiative
Earlier this month, Tempus AI announced a multi‑year initiative to build a research platform of 100,000 whole genomes linked to longitudinal clinical, imaging, pathology and outcome data, with plans to eventually scale toward one million genomes and offer broad access via its Tempus Lens environment by mid‑2027. This move extends Tempus AI beyond targeted panels into whole‑genome sequencing, creating a model‑ready, multimodal dataset specifically tailored for AI‑driven disease and drug...
Tempus AI (TEM) Unveils Whole Genome Platform With Plans For 1 Million Genomes
Tempus AI (NasdaqGS:TEM) announced a new whole-genome sequencing initiative linked to clinical data for AI research in September 2026. The project aims to create a de-identified multimodal dataset that connects full genome reads with real-world clinical and imaging records. Management targets scaling the platform to one million whole genomes tied to patient outcomes for use in drug development and personalized care. This new whole-genome sequencing and clinical data platform comes against a...
The ARK Trade Watch: Cathie Wood Cuts Crypto Exposure, Then Reverses Course On CoreWeave
Cathie Wood's ARK Invest funds made a broad move out of crypto-linked assets during the week, led by the sale of more than 1.5 million shares of the ARK 21Shares Bitcoin ETF.
Why Is Tempus AI Stock Falling Friday?
Tempus AI stock pulled back Friday but stays firmly above key moving averages. Is the TEM rally still intact? Read more.
Strength Seen in Tempus (TEM): Can Its 14.9% Jump Turn into More Strength?
Tempus (TEM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks Investment Ideas feature highlights: NVIDIA, Advanced Micro Devices, Tempus, Moderna, Super Micro Computer and Aya Gold & Silver
NVIDIA, Advanced Micro Devices, Tempus, Moderna, Super Micro Computer and Aya Gold & Silver have been highlighted in this Investment Ideas article.
Will 2026 Doom and Gloom Lead to Opportunity?
While macroeconomic headwinds, geopolitical energy shocks, and relentless media fear-mongering might suggest a market correction is overdue, the resilience of stock price action tells a different story.
Tempus AI Stock Surges as Revenue Optimism Boosts Winning Streak
Clarity on how much revenue Tempus AI will bring in through Medicare reimbursements for two of its cancer screenings appeased investors this week as shares surged Thursday. Tempus stock added 15% Thursday as part of a 36% advance over the last five sessions. in which Tempus is the third-largest position behind Tesla and SpaceX rose 4.3%.
Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook
Morgan Stanley just reframed the revenue story for Tempus AI in a way that management's own guidance never fully captured, and the market is now scrambling to catch up with what reimbursement clarity actually means for the bottom line.
Nasdaq 100 Rallies as Oil Slides, Yields Retreat: Stock Market Today
Wall Street snapped a two-day losing streak Thursday as oil retreated from its geopolitical spike and the 10-year Treasury yield slipped back below 5%. Chipmakers led the rebound, with Intel, AMD and Micron all posting outsized gains, while gold climbed 2.5% to $4,369 an ounce. The bounce came one day after the Federal Reserve delivered its first interest rate hike since 2023 and signaled at least one more this year.
Vicor, Arm Holdings, Micron Technology And Other Big Stocks Moving Higher On Thursday
U.S. stocks rose; Vicor jumped 13.5% on a new license, while Generac surged 19.6% on an Amazon deal. Securitize and biotech shares rallied.
Novo Nordisk, Anthropic Team Up For AI Drug Research
Novo Nordisk taps Anthropic AI to speed medicine research, enhance software workflows, and implement responsible data governance standards.
Neuraxis Gains Nearly 137% in a Year: What's Driving the Stock?
NRXS is benefiting from stronger IB-Stim volumes, broader reimbursement and VA access, but incomplete payer coverage and cash needs remain challenges.
10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today
The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi pipeline outages, pressuring stocks ahead of the Fed.
Tempus AI, Inc. (TEM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Tempus AI, Inc. (TEM) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 8:30 AM EDTCompany ParticipantsEric Lefkofsky - Co-Founder,...
'Tempus AI Founder Supports Anthropic CEO’s Call for Slowdown' - Bloomberg News
https://www.bloomberg.com/news/articles/2026-09-14/tempus-ai-founder-supports-anthropic-ceo-s-call-for-slowdown
Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation
CHICAGO, September 11, 2026--Tempus AI, Inc. (NASDAQ: TEM) today announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years. The effort will create the first de-identified multimodal whole-genome sequencing (WGS) dataset built around disease populations and patient outcomes, specifically optimized for AI-driven research. Once this dataset is complete, Tempus plans to expand the effort with the goal
Nvidia, Snowflake, Chubb And A Health Care Stock On CNBC’s ‘Final Trades’
CNBC’s final trades: Joshua Brown picked Snowflake, Bill Baruch chose Tempus AI, Malcolm Ethridge favored Chubb, and Stephanie Link recommended Nvidia.
Tempus AI Announces Initiative To Build Research Platform Containing 100K Whole Genomes Linked To Longitudinal Clinical Information Over Next Several Years
The Initiative Will Make Available 100,000 Disease-Specific Whole Genome Sequences Paired with Longitudinal Clinical Outcomes, with a Long-Term Goal of Reaching 1 Million GenomesTempus AI, Inc. (NASDAQ:TEM) today
HC Wainwright & Co. Maintains Buy on Tempus AI, Raises Price Target to $66
HC Wainwright & Co. analyst Yi Chen maintains Tempus AI (NASDAQ:TEM) with a Buy and raises the price target from $56 to $66.
Tempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in Cardiology
CHICAGO, September 09, 2026--Tempus AI, Inc. (NASDAQ: TEM) today announced that it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to receive an award of up to $9.5 million to build the first autonomous clinical AI agent capable of providing safe and effective care to patients suffering from heart failure. Funding provided through ARPA-H’s ADVOCATE (Agentic AI-EnableD CardioVascular CAre TransfOrma
Tempus AI Selected By Advanced Research Projects Agency For Health To Be Awarded $9.5M For First Autonomous Clinical AI Agent
Tempus AI, Inc. (NASDAQ: TEM) today announced that it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to receive an
Cathie Wood Grows Robinhood Stake; Sheds More AMD, Palantir
Cathie Wood's firm ARK Invest added to its already sizable position in the trading platform Robinhood, which is back in a buy zone.
UBS Initiates Coverage On Tempus AI with Neutral Rating, Announces Price Target of $70
UBS analyst Doug Schenkel initiates coverage on Tempus AI (NASDAQ:TEM) with a Neutral rating and announces Price Target of $70.
Rothschild & Co Initiates Coverage On Tempus AI with Neutral Rating, Announces Price Target of $67
Rothschild & Co analyst Jamie Clark initiates coverage on Tempus AI (NASDAQ:TEM) with a Neutral rating and announces Price Target of $67.
Roth Capital Initiates Coverage On Tempus AI with Neutral Rating, Announces Price Target of $67
Roth Capital analyst Jamie Clark initiates coverage on Tempus AI (NASDAQ:TEM) with a Neutral rating and announces Price Target of $67.
The Cure for Cancer is Becoming an Investable Opportunity: Analyst Sees $600 Million for Tempus AI
Personalized cancer vaccines are creating a diagnostics investment opportunity beyond Moderna and Merck, with tumor sequencing at its center.
Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
CHICAGO, September 04, 2026--Tempus AI, Inc. (NASDAQ: TEM) today announced that Founder and CEO Eric Lefkofsky will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 8:30 a.m. ET in New York City.
Hinge Health Inc. (HNGE) Up 13.7% Since Last Earnings Report: Can It Continue?
Hinge Health Inc. (HNGE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Moderna's Cancer Vaccine Matters To Investors
As legacy pharmaceutical models face structural challenges, targeting the underlying technology enablers of next-generation care offers a compelling approach for healthcare investors.
AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030
Equity Insider News Commentary - Pharmaceutical research is being rebuilt around artificial intelligence faster than the industry can absorb it. Arizton values the global AI in drug discovery market at approximately $1.71 billion in 2024 and projects it will reach roughly $8.52 billion by 2030, a compound annual growth rate of about 30.58%. That is a market compounding at more than double the rate of most enterprise software categories, and it is being spent inside an industry that already inves
Tempus AI Got an $80 Target and 28% Upside Call. Is Wall Street Underestimating Its Healthcare Data Moat?
Tempus AI received a fresh vote of confidence on September 2 as Cantor Fitzgerald initiated coverage with an Overweight rating and an $80 price target. From the roughly $62.27 price cited with the call, that implied about 28% upside. The argument centers on a difficult-to-replicate combination: clinical data, diagnostics, software, and artificial intelligence operating inside […]
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-25 | Schoenherr Thomas Edward | -10,281 | $85 | $873,885 |
| 2026-09-22 | LEFKOFSKY ERIC P | -160 | $78.86 | $12,618 |
| 2026-09-22 | LEFKOFSKY ERIC P | -14,042 | $78.23 | $1,098,506 |
| 2026-09-22 | LEFKOFSKY ERIC P | -29,367 | $77.29 | $2,269,775 |
| 2026-09-22 | LEFKOFSKY ERIC P | -6,431 | $76.57 | $492,422 |
| 2026-09-22 | LEFKOFSKY ERIC P | -24 | $78.86 | $1,893 |
| 2026-09-22 | LEFKOFSKY ERIC P | -2,091 | $78.23 | $163,579 |
| 2026-09-22 | LEFKOFSKY ERIC P | -4,420 | $77.29 | $341,622 |
| 2026-09-22 | LEFKOFSKY ERIC P | -965 | $76.57 | $73,890 |
| 2026-09-22 | LEFKOFSKY ERIC P | -432 | $78.86 | $34,068 |
| 2026-09-22 | LEFKOFSKY ERIC P | -37,950 | $78.23 | $2,968,829 |
| 2026-09-22 | LEFKOFSKY ERIC P | -79,259 | $77.29 | $6,125,928 |
| 2026-09-22 | LEFKOFSKY ERIC P | -17,359 | $76.57 | $1,329,179 |
| 2026-09-22 | LEFKOFSKY ERIC P | -184 | $78.86 | $14,510 |
| 2026-09-22 | LEFKOFSKY ERIC P | -16,152 | $78.23 | $1,263,571 |
| 2026-09-22 | LEFKOFSKY ERIC P | -33,770 | $77.29 | $2,610,083 |
| 2026-09-22 | LEFKOFSKY ERIC P | -7,394 | $76.57 | $566,159 |
| 2026-09-17 | Polovin Andrew | -2,951 | $75 | $221,325 |
| 2026-09-17 | Bartolucci Ryan M | -7,062 | $75 | $529,650 |
| 2026-09-17 | LEFKOFSKY ERIC P | -645 | $81.09 | $52,303 |
| 2026-09-17 | LEFKOFSKY ERIC P | -6,855 | $80.52 | $551,965 |
| 2026-09-17 | LEFKOFSKY ERIC P | -11,609 | $81.09 | $941,374 |
| 2026-09-17 | LEFKOFSKY ERIC P | -123,391 | $80.52 | $9,935,443 |
| 2026-09-17 | LEFKOFSKY ERIC P | -4,942 | $81.09 | $400,747 |
| 2026-09-17 | LEFKOFSKY ERIC P | -52,558 | $80.52 | $4,231,970 |
| 2026-09-16 | Fukushima Ryan | -700 | $70 | $49,000 |
| 2026-09-01 | Fukushima Ryan | -1,000 | $64.63 | $64,630 |
| 2026-09-01 | Fukushima Ryan | -5,900 | $63.8 | $376,420 |
| 2026-09-01 | Fukushima Ryan | -10,900 | $62.64 | $682,776 |
| 2026-09-01 | Fukushima Ryan | -13,046 | $62.12 | $810,418 |
| 2026-09-01 | Doudna Jennifer A | -676 | $65.55 | $44,312 |
| 2026-09-01 | Epstein David R | -250 | $65.55 | $16,388 |
| 2026-08-28 | West Nadja | -3,000 | $69 | $207,000 |
| 2026-08-25 | LEFKOFSKY ERIC P | -681 | $70.58 | $48,065 |
| 2026-08-25 | LEFKOFSKY ERIC P | -11,167 | $69.83 | $779,792 |
| 2026-08-25 | LEFKOFSKY ERIC P | -19,605 | $68.97 | $1,352,157 |
| 2026-08-25 | LEFKOFSKY ERIC P | -8,926 | $68.13 | $608,128 |
| 2026-08-25 | LEFKOFSKY ERIC P | -3,649 | $67.01 | $244,519 |
| 2026-08-25 | LEFKOFSKY ERIC P | -3,429 | $65.98 | $226,245 |
| 2026-08-25 | LEFKOFSKY ERIC P | -1,883 | $64.7 | $121,830 |
| 2026-08-25 | LEFKOFSKY ERIC P | -660 | $64.03 | $42,260 |
| 2026-08-25 | LEFKOFSKY ERIC P | -102 | $70.58 | $7,199 |
| 2026-08-25 | LEFKOFSKY ERIC P | -1,668 | $69.83 | $116,476 |
| 2026-08-25 | LEFKOFSKY ERIC P | -2,887 | $68.96 | $199,088 |
| 2026-08-25 | LEFKOFSKY ERIC P | -1,365 | $68.13 | $92,997 |
| 2026-08-25 | LEFKOFSKY ERIC P | -578 | $67.01 | $38,732 |
| 2026-08-25 | LEFKOFSKY ERIC P | -515 | $65.98 | $33,980 |
| 2026-08-25 | LEFKOFSKY ERIC P | -284 | $64.7 | $18,375 |
| 2026-08-25 | LEFKOFSKY ERIC P | -101 | $64.03 | $6,467 |
| 2026-08-25 | LEFKOFSKY ERIC P | -1,837 | $70.58 | $129,655 |
| 2026-08-25 | LEFKOFSKY ERIC P | -30,139 | $69.83 | $2,104,606 |
| 2026-08-25 | LEFKOFSKY ERIC P | -52,784 | $68.97 | $3,640,512 |
| 2026-08-25 | LEFKOFSKY ERIC P | -24,161 | $68.13 | $1,646,089 |
| 2026-08-25 | LEFKOFSKY ERIC P | -9,935 | $67.01 | $665,744 |
| 2026-08-25 | LEFKOFSKY ERIC P | -9,262 | $65.98 | $611,107 |
| 2026-08-25 | LEFKOFSKY ERIC P | -5,093 | $64.7 | $329,517 |
| 2026-08-25 | LEFKOFSKY ERIC P | -1,789 | $64.03 | $114,550 |
| 2026-08-25 | LEFKOFSKY ERIC P | -782 | $70.58 | $55,194 |
| 2026-08-25 | LEFKOFSKY ERIC P | -12,851 | $69.83 | $897,385 |
| 2026-08-25 | LEFKOFSKY ERIC P | -22,495 | $68.97 | $1,551,480 |
| 2026-08-25 | LEFKOFSKY ERIC P | -10,282 | $68.13 | $700,513 |
| 2026-08-25 | LEFKOFSKY ERIC P | -4,218 | $67.01 | $282,648 |
| 2026-08-25 | LEFKOFSKY ERIC P | -3,944 | $65.98 | $260,225 |
| 2026-08-25 | LEFKOFSKY ERIC P | -2,168 | $64.7 | $140,270 |
| 2026-08-25 | LEFKOFSKY ERIC P | -760 | $64.03 | $48,663 |
| 2026-08-21 | Schoenherr Thomas Edward | +2,694 | $70 | $188,580 |
| 2026-08-21 | Fukushima Ryan | -14,286 | $70 | $1,000,020 |
| 2026-08-19 | Schoenherr Thomas Edward | -494 | $61.23 | $30,248 |
| 2026-08-19 | Schoenherr Thomas Edward | -900 | $60.45 | $54,405 |
| 2026-08-19 | Schoenherr Thomas Edward | -2,994 | $59.97 | $179,550 |
| 2026-08-19 | Schoenherr Thomas Edward | -500 | $57.94 | $28,970 |
| 2026-08-19 | Schoenherr Thomas Edward | -100 | $56.47 | $5,647 |
| 2026-08-19 | Schoenherr Thomas Edward | -3,094 | $55.97 | $173,171 |
| 2026-08-19 | Rogers James William | -26,313 | $60 | $1,578,780 |
| 2026-08-19 | Polovin Andrew | -7,927 | $56 | $443,912 |
| 2026-08-18 | Schoenherr Thomas Edward | -9,232 | $49.61 | $458,000 |
| 2026-08-18 | Rogers James William | -22,529 | $49.61 | $1,117,664 |
| 2026-08-18 | Fukushima Ryan | -41,095 | $49.61 | $2,038,723 |
| 2026-08-18 | Polovin Andrew | -22,148 | $49.61 | $1,098,762 |
| 2026-08-18 | Bartolucci Ryan M | -6,175 | $49.61 | $306,342 |
| 2026-08-18 | LEFKOFSKY ERIC P | -132,591 | $49.61 | $6,577,840 |
| 2026-08-14 | West Nadja | -3,000 | $53.9 | $161,700 |
| 2026-08-12 | Fukushima Ryan | -62,239 | - | - |
| 2026-08-07 | Fukushima Ryan | -20,000 | $50.04 | $1,000,800 |
| 2026-08-03 | Fukushima Ryan | -2,562 | $46.94 | $120,260 |
| 2026-08-03 | Fukushima Ryan | -15,856 | $46.57 | $738,414 |
| 2026-08-03 | Fukushima Ryan | -3,100 | $45.33 | $140,523 |
| 2026-08-03 | Fukushima Ryan | -1,300 | $44.33 | $57,629 |
| 2026-08-03 | Fukushima Ryan | -1,000 | $43.25 | $43,250 |
| 2026-08-03 | Epstein David R | -370 | $43.4 | $16,058 |
| 2026-07-29 | Rogers James William | +40,000 | - | - |
| 2026-07-29 | Polovin Andrew | +40,000 | - | - |
| 2026-07-28 | LEFKOFSKY ERIC P | -5,324 | $42.95 | $228,666 |
| 2026-07-28 | LEFKOFSKY ERIC P | -26,875 | $42.36 | $1,138,425 |
| 2026-07-28 | LEFKOFSKY ERIC P | -17,801 | $41.34 | $735,893 |
| 2026-07-28 | LEFKOFSKY ERIC P | -798 | $42.95 | $34,274 |
| 2026-07-28 | LEFKOFSKY ERIC P | -4,031 | $42.36 | $170,753 |
| 2026-07-28 | LEFKOFSKY ERIC P | -2,671 | $41.34 | $110,419 |
| 2026-07-28 | LEFKOFSKY ERIC P | -14,374 | $42.95 | $617,363 |
| 2026-07-28 | LEFKOFSKY ERIC P | -72,560 | $42.36 | $3,073,642 |
| 2026-07-28 | LEFKOFSKY ERIC P | -48,066 | $41.34 | $1,987,048 |
| 2026-07-28 | LEFKOFSKY ERIC P | -6,122 | $42.95 | $262,940 |
| 2026-07-28 | LEFKOFSKY ERIC P | -30,906 | $42.36 | $1,309,178 |
| 2026-07-28 | LEFKOFSKY ERIC P | -20,472 | $41.34 | $846,312 |
| 2026-07-08 | Fukushima Ryan | -2,137 | $59.47 | $127,087 |
| 2026-07-08 | Fukushima Ryan | -3,477 | $58.55 | $203,578 |
| 2026-07-08 | Fukushima Ryan | -13,686 | $57.37 | $785,166 |
| 2026-07-08 | Fukushima Ryan | -13,984 | $56.8 | $794,291 |
| 2026-07-06 | Fukushima Ryan | -10,000 | $60 | $600,000 |
| 2026-06-29 | LEFKOFSKY ERIC P | -36,520 | $59.23 | $2,163,080 |
| 2026-06-29 | LEFKOFSKY ERIC P | -8,320 | $58.3 | $485,056 |
| 2026-06-29 | LEFKOFSKY ERIC P | -41,178 | $57.13 | $2,352,499 |
| 2026-06-29 | LEFKOFSKY ERIC P | -37,711 | $56.51 | $2,131,049 |
| 2026-06-29 | LEFKOFSKY ERIC P | -9,271 | $55.38 | $513,428 |
| 2026-06-29 | LEFKOFSKY ERIC P | -9,130 | $59.23 | $540,770 |
| 2026-06-29 | LEFKOFSKY ERIC P | -2,080 | $58.3 | $121,264 |
| 2026-06-29 | LEFKOFSKY ERIC P | -10,293 | $57.13 | $588,039 |
| 2026-06-29 | LEFKOFSKY ERIC P | -9,430 | $56.51 | $532,889 |
| 2026-06-29 | LEFKOFSKY ERIC P | -2,317 | $55.38 | $128,315 |
| 2026-06-01 | Epstein David R | -250 | $49.4 | $12,350 |
| 2026-05-27 | LEFKOFSKY ERIC P | -97,279 | $46.89 | $4,561,412 |
| 2026-05-27 | LEFKOFSKY ERIC P | -35,721 | $46.17 | $1,649,239 |
| 2026-05-27 | LEFKOFSKY ERIC P | -24,318 | $46.89 | $1,140,271 |
| 2026-05-27 | LEFKOFSKY ERIC P | -8,932 | $46.17 | $412,390 |
| 2026-05-21 | Frederick Wayne A.I. | +5,913 | - | - |
| 2026-05-21 | West Nadja | +5,913 | - | - |
| 2026-05-21 | Doudna Jennifer A | +5,913 | - | - |
| 2026-05-21 | Leonsis Theodore | +5,913 | - | - |
| 2026-05-21 | Epstein David R | +5,913 | - | - |
| 2026-05-21 | Gottlieb Scott | +5,913 | - | - |
| 2026-05-21 | Belcher Eric D | +5,913 | - | - |
| 2026-05-21 | BARRIS PETER J | +5,913 | - | - |
| 2026-05-19 | Schoenherr Thomas Edward | -1,580 | $44.07 | $69,631 |
| 2026-05-19 | Rogers James William | -10,853 | $44.07 | $478,292 |
| 2026-05-19 | Fukushima Ryan | -13,550 | $44.07 | $597,149 |
| 2026-05-19 | Polovin Andrew | -8,703 | $44.07 | $383,541 |
| 2026-05-19 | Bartolucci Ryan M | -4,116 | $44.07 | $181,392 |
| 2026-05-19 | LEFKOFSKY ERIC P | -22,335 | $44.07 | $984,303 |
| 2026-05-14 | Fukushima Ryan | +62,239 | - | - |
| 2026-05-14 | Fukushima Ryan | -162,239 | - | - |
| 2026-05-04 | Rogers James William | +10,000 | - | - |
| 2026-05-04 | Fukushima Ryan | +10,000 | - | - |
| 2026-05-04 | Polovin Andrew | +10,000 | - | - |
| 2026-05-04 | Bartolucci Ryan M | +24,000 | - | - |
| 2026-05-04 | Schoenherr Thomas Edward | +13,642 | - | - |
| 2026-04-28 | LEFKOFSKY ERIC P | -27,570 | $51.52 | $1,420,406 |
| 2026-04-28 | LEFKOFSKY ERIC P | -105,430 | $51.03 | $5,380,093 |
| 2026-04-28 | LEFKOFSKY ERIC P | -6,890 | $51.52 | $354,973 |
| 2026-04-28 | LEFKOFSKY ERIC P | -26,360 | $51.03 | $1,345,151 |
| 2026-03-26 | LEFKOFSKY ERIC P | -7,784 | $47.42 | $369,117 |
| 2026-03-26 | LEFKOFSKY ERIC P | -59,657 | $46.91 | $2,798,510 |
| 2026-03-26 | LEFKOFSKY ERIC P | -65,559 | $45.78 | $3,001,291 |
| 2026-03-26 | LEFKOFSKY ERIC P | -1,947 | $47.42 | $92,327 |
| 2026-03-26 | LEFKOFSKY ERIC P | -14,915 | $46.91 | $699,663 |
| 2026-03-26 | LEFKOFSKY ERIC P | -16,388 | $45.78 | $750,243 |
| 2026-03-02 | Rogers James William | -11,414 | $50.69 | $578,576 |
| 2026-03-02 | Epstein David R | -250 | $50.69 | $12,673 |
| 2026-02-20 | Rogers James William | +37,496 | - | - |
| 2026-02-20 | Fukushima Ryan | +74,993 | - | - |
| 2026-02-20 | Polovin Andrew | -100 | $60.97 | $6,097 |
| 2026-02-20 | Polovin Andrew | -10,849 | $60.3 | $654,195 |
| 2026-02-20 | Polovin Andrew | +38,420 | - | - |
| 2026-02-20 | Bartolucci Ryan M | +12,998 | - | - |
| 2026-02-20 | LEFKOFSKY ERIC P | +263,430 | - | - |
| 2026-02-19 | Rogers James William | -10,084 | $59.05 | $595,460 |
| 2026-02-19 | Fukushima Ryan | -9,592 | $59.05 | $566,408 |
| 2026-02-19 | Phelps Erik | -5,650 | $59.05 | $333,633 |
| 2026-02-19 | Phelps Erik | -3,814 | $60 | $228,840 |
| 2026-02-19 | Polovin Andrew | -8,143 | $59.05 | $480,844 |
| 2026-02-19 | Bartolucci Ryan M | -2,902 | $59.05 | $171,363 |
| 2026-02-19 | LEFKOFSKY ERIC P | -13,587 | $59.05 | $802,312 |
| 2026-02-19 | LEFKOFSKY ERIC P | -3,716 | $59.7 | $221,845 |
| 2026-02-19 | LEFKOFSKY ERIC P | -95,567 | $59.04 | $5,642,276 |
| 2026-02-19 | LEFKOFSKY ERIC P | -33,717 | $58.31 | $1,966,038 |
| 2026-02-19 | LEFKOFSKY ERIC P | -923 | $59.7 | $55,103 |
| 2026-02-19 | LEFKOFSKY ERIC P | -23,775 | $59.04 | $1,403,676 |
| 2026-02-19 | LEFKOFSKY ERIC P | -8,552 | $58.31 | $498,667 |
| 2026-02-02 | Epstein David R | -370 | $59.41 | $21,982 |
| 2026-01-28 | LEFKOFSKY ERIC P | -30,526 | $66.06 | $2,016,548 |
| 2026-01-28 | LEFKOFSKY ERIC P | -102,474 | $65.41 | $6,702,824 |
| 2026-01-28 | LEFKOFSKY ERIC P | -7,619 | $66.06 | $503,311 |
| 2026-01-28 | LEFKOFSKY ERIC P | -25,631 | $65.41 | $1,676,524 |
| 2026-01-05 | Fukushima Ryan | -5,000 | $64.26 | $321,300 |
| 2026-01-02 | Doudna Jennifer A | -1,250 | $60.17 | $75,213 |
| 2025-12-18 | LEFKOFSKY ERIC P | -11,207 | $66.04 | $740,110 |
| 2025-12-18 | LEFKOFSKY ERIC P | -11,238 | $64.92 | $729,571 |
| 2025-12-18 | LEFKOFSKY ERIC P | -75,913 | $64.12 | $4,867,542 |
| 2025-12-18 | LEFKOFSKY ERIC P | -20,489 | $63.08 | $1,292,446 |
| 2025-12-18 | LEFKOFSKY ERIC P | -14,153 | $62.26 | $881,166 |
| 2025-12-18 | LEFKOFSKY ERIC P | -2,801 | $66.04 | $184,978 |
| 2025-12-18 | LEFKOFSKY ERIC P | -2,800 | $64.92 | $181,776 |
| 2025-12-18 | LEFKOFSKY ERIC P | -18,960 | $64.12 | $1,215,715 |
| 2025-12-18 | LEFKOFSKY ERIC P | -5,118 | $63.08 | $322,843 |
| 2025-12-18 | LEFKOFSKY ERIC P | -3,571 | $62.26 | $222,330 |
| 2025-12-16 | Phelps Erik | -1,302 | $67.42 | $87,781 |
| 2025-12-11 | Rogers James William | -3,775 | $74.08 | $279,652 |
| 2025-12-11 | Rogers James William | -11,982 | $73.31 | $878,400 |
| 2025-12-11 | Rogers James William | -4,209 | $72.09 | $303,427 |
| 2025-12-05 | Frederick Wayne A.I. | -3,675 | $77.23 | $283,820 |
| 2025-12-01 | Fukushima Ryan | -1,968 | $76.39 | $150,336 |
| 2025-12-01 | Fukushima Ryan | -2,128 | $75.59 | $160,856 |
| 2025-12-01 | Fukushima Ryan | -904 | $74.59 | $67,429 |
| 2025-12-01 | Doudna Jennifer A | -676 | $75.55 | $51,072 |
| 2025-12-01 | Epstein David R | -250 | $75.55 | $18,888 |
| 2025-11-25 | Fukushima Ryan | -131,893 | - | - |
| 2025-11-25 | Fukushima Ryan | +33,808 | - | - |
| 2025-11-25 | Fukushima Ryan | -125,135 | - | - |
| 2025-11-24 | Polovin Andrew | -12,874 | $75 | $965,550 |
| 2025-11-24 | LEFKOFSKY ERIC P | -133,000 | $74.1 | $9,855,300 |
| 2025-11-24 | LEFKOFSKY ERIC P | -33,250 | $74.1 | $2,463,825 |
| 2025-11-20 | LEFKOFSKY ERIC P | -15,138 | $72.2 | $1,092,964 |
| 2025-11-20 | LEFKOFSKY ERIC P | -35,362 | $71.63 | $2,532,980 |
| 2025-11-20 | LEFKOFSKY ERIC P | -12,295 | $70.58 | $867,781 |
| 2025-11-20 | LEFKOFSKY ERIC P | -8,158 | $69.43 | $566,410 |
| 2025-11-20 | LEFKOFSKY ERIC P | -3,640 | $68.38 | $248,903 |
| 2025-11-20 | LEFKOFSKY ERIC P | -7,660 | $67.39 | $516,207 |
| 2025-11-20 | LEFKOFSKY ERIC P | -25,866 | $66.33 | $1,715,692 |
| 2025-11-20 | LEFKOFSKY ERIC P | -24,881 | $65.59 | $1,631,945 |
| 2025-11-20 | LEFKOFSKY ERIC P | -3,783 | $72.2 | $273,133 |
| 2025-11-20 | LEFKOFSKY ERIC P | -8,841 | $71.63 | $633,281 |
| 2025-11-20 | LEFKOFSKY ERIC P | -3,074 | $70.58 | $216,963 |
| 2025-11-20 | LEFKOFSKY ERIC P | -2,041 | $69.43 | $141,707 |
| 2025-11-20 | LEFKOFSKY ERIC P | -910 | $68.38 | $62,226 |
| 2025-11-20 | LEFKOFSKY ERIC P | -1,913 | $67.39 | $128,917 |
| 2025-11-20 | LEFKOFSKY ERIC P | -6,467 | $66.33 | $428,956 |
| 2025-11-20 | LEFKOFSKY ERIC P | -6,221 | $65.59 | $408,035 |
| 2025-11-19 | Polovin Andrew | -200 | $69.41 | $13,882 |
| 2025-11-19 | Polovin Andrew | -2,052 | $68.86 | $141,301 |
| 2025-11-19 | Polovin Andrew | -3,307 | $67.9 | $224,545 |
| 2025-11-19 | Polovin Andrew | -828 | $66.4 | $54,979 |
| 2025-11-18 | Rogers James William | -2,269 | $66.15 | $150,094 |
| 2025-11-18 | Rogers James William | -4,988 | $65.26 | $325,517 |
| 2025-11-18 | Fukushima Ryan | -3,157 | $66.15 | $208,836 |
| 2025-11-18 | Fukushima Ryan | -6,942 | $65.26 | $453,035 |
| 2025-11-18 | Phelps Erik | -1,105 | $66.15 | $73,096 |
| 2025-11-18 | Phelps Erik | -2,428 | $65.26 | $158,451 |
| 2025-11-18 | Polovin Andrew | -1,627 | $66.15 | $107,626 |
| 2025-11-18 | Polovin Andrew | -3,578 | $65.26 | $233,500 |
| 2025-11-18 | Bartolucci Ryan M | -573 | $66.15 | $37,904 |
| 2025-11-18 | Bartolucci Ryan M | -1,261 | $65.26 | $82,293 |
| 2025-11-18 | LEFKOFSKY ERIC P | -5,262 | $66.15 | $348,081 |
| 2025-11-18 | LEFKOFSKY ERIC P | -11,567 | $65.26 | $754,862 |
| 2025-11-11 | Doudna Jennifer A | -1,926 | $71.45 | $137,613 |
| 2025-11-03 | Fukushima Ryan | -2,200 | $89.64 | $197,208 |
| 2025-11-03 | Fukushima Ryan | -2,300 | $88.84 | $204,332 |
| 2025-11-03 | Fukushima Ryan | -500 | $87.24 | $43,620 |
| 2025-11-03 | Epstein David R | -370 | $90 | $33,300 |
| 2025-10-28 | LEFKOFSKY ERIC P | -3,903 | $91.55 | $357,320 |
| 2025-10-28 | LEFKOFSKY ERIC P | -34,841 | $90.28 | $3,145,445 |
| 2025-10-28 | LEFKOFSKY ERIC P | -120,794 | $89.5 | $10,811,063 |
| 2025-10-28 | LEFKOFSKY ERIC P | -70,472 | $88.59 | $6,243,114 |
| 2025-10-28 | LEFKOFSKY ERIC P | -35,990 | $87.42 | $3,146,246 |
| 2025-10-28 | LEFKOFSKY ERIC P | -975 | $91.55 | $89,261 |
| 2025-10-28 | LEFKOFSKY ERIC P | -8,723 | $90.28 | $787,512 |
| 2025-10-28 | LEFKOFSKY ERIC P | -30,190 | $89.5 | $2,702,005 |
| 2025-10-28 | LEFKOFSKY ERIC P | -17,622 | $88.59 | $1,561,133 |
| 2025-10-28 | LEFKOFSKY ERIC P | -8,990 | $87.42 | $785,906 |
| 2025-10-06 | Fukushima Ryan | -2,623 | $92.96 | $243,834 |
| 2025-10-06 | Fukushima Ryan | -1,662 | $91.95 | $152,821 |
| 2025-10-06 | Fukushima Ryan | -715 | $90.84 | $64,951 |